Resectable Non–Small Cell Lung Cancer: Neoadjuvant Treatment Strategies
Focused discussion on the selection of neoadjuvant therapy in patients with resectable NSCLC in light of recent clinical trials.
Source: onclive.com
Page 2 - Pathologic Complete Response News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Pathologic Complete Response. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Pathologic Complete Response Today - Breaking & Trending Today
Immunotherapy improves lung cancer outcomes
Immunotherapy given before and after surgery significantly improved outcomes in patients with operable non-small cell lung cancer.
Source: scienceboard.net
Agendia, Inc.: Data Presented at the Miami Breast Cancer Conference Show MammaPrint and BluePrint Accurately Predict Pathologic Complete Response Rate Regardless of Age
(1) Results support use of Agendia's genomic tests to better tailor pre-operative treatment and timing for surgery Agendia, Inc., a world leader in precision oncology for breast cancer, announced new data from the prospective Neoadjuvant Breast Symphony Trial (NBRST) which demonstrate the predictive and prognostic abilities of MammaPrint and BluePrint , and underpin both assays' pre-operative utility in pre-and post-menopausal patients. A poster highlighting these findings will be presented at the 38 th Annual Miami Breast Cancer Conference. The poster, entitled Pathologic Complete Response...
Source: finanznachrichten.de